Irpagratinib

Overview

Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC 50 <10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model.

Application

Products | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-156618
• CAS No.: 2230974-62-4
• Molecular Formula: C28H32F2N6O5
• Molecular Weight: 570.59
• Purity: 99.61%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (4.38 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source